494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas

Ngā tūemi rite

• Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
  mā: Xianlong Chen, me ētahi atu.
  I whakaputaina: (2022-07-01)
• Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors
  mā: Daniele E. Mascarelli, me ētahi atu.
  I whakaputaina: (2021-06-01)
• OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
  mā: Ana Maria Lé, me ētahi atu.
  I whakaputaina: (2022-12-01)
• OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress
  mā: Zixuan Yuan, me ētahi atu.
  I whakaputaina: (2026-01-01)
• A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab
  mā: Asaad Abdelhalim, me ētahi atu.
  I whakaputaina: (2024-11-01)